| abstract |
The present invention relates to compositions and methods for modulating NK cell activity. The present invention relates to an antibody specifically binding to KIR2DL1, KIR2DL2 and/or KIR2DL3, comprising: heavy chain CDR1 consisting of the amino acid sequence GFSFTPYGVH, heavy chain CDR2 consisting of the amino acid sequence VIWSGGNTDYNAAFIS, and heavy chain CDR3 consisting of the amino acid sequence NPRPGNYPYGMDY , the light chain CDR1 consisting of the amino acid sequence KASENVVTYVS, the light chain CDR2 consisting of the amino acid sequence GASNRYT, and the light chain CDR3 consisting of the amino acid sequence GQGYSYPYT. The invention also relates to pharmaceutical compositions comprising such antibodies and their use, especially in therapy, to increase NK cell activity or cytotoxicity in a subject. |